Today, we have an update from the MMTP Project team. The project was launched on Lifespan.io back in 2016 with the aim of testing senolytics and their effect on lifespan, it was successfully funded and raised 15% over its initial goal.
Hi everyone, it has been a long time so we thought it was time for a small update. We wanted to let you all know that the mouse study has been significantly delayed due to the strict regulations in Germany concerning animal welfare. In Germany, there is a lot of paperwork to complete and high standards to reach before permission is granted for an animal study. Dr. Stolzing continues to work with government representatives and the animal testing factility in Leipzig to move things forward, though it is likely additional ethics reviews will be required by the authorities.
Meanwhile we are going to conduct in vitro testing using six different senolytic or potentially senolytic drugs in various combinations, as multiple previous tests on senolytics done by other groups suggest that each one favors a different cell type. There are no previous studies exploring the potential of combinations of senolytics, with the exception of the work done with dasatinib and quercetin.
Many of the compounds that we are testing are known to target different types of senescent cells; therefore, a combination could potentially improve their efficiency, as Dr. Peter de Keizer recently suggested when he discussed senolytic “cocktails”.
Thank you once again to all our generous supporters who helped make the project a reality, and we hope that it leads to some interesting results once the research team publishes its findings.
The MMTP Team